FP135RENAL BIOPSY DURING PREGNANCY:ABOUT FOURTEEN CASES

Le résumé fourni par la source

Introduction and Aims: The security of the renal biopsy (RB) during pregnancy is a matter of debate. However, it may be imperative. The purpose of this study was to evaluate the role of PBR in diagnosing kidney damage during pregnancy and to check its innocuousness Methods: A retrospective study of 14 RB echo-guided conducted in 14 pregnant women with renal disease. The clinical and biological characteristic (24 h proteinuria, creatininemia, protidemia, albuminemia and hematuria) are analyzed. The indications for renal biopsy are noted and the treatments used. Toxemic patients are excluded. Results: The mean age was 32.8± 8 years. 8 are multiparous and 6 nulliparous. Gestational age was 16 ± 5 weeks of amenorrhea. Indications for RB were nephrotic syndrome in 12 cases, recurrent macroscopic hematuria in 1 case and 1 patient with renal failure and hypertension. The average systolic blood pressure was 130 ± 20 mmHg and diastolic 76± 15 mmHg. The average rate of proteinuria of 24h is 3.9 ± 5.4 g/24 h, creatininemia was 10± 4 mg / L plasma protein was 50,6 ± 5 g / L and albuminemia was 20± 5g / L. The RB showed minimal change disease (MCD) in 4 cases, Extramembranous glomerulonephritis (EMG) in 4 cases, lupus nephritis (LN) class IV in 3 cases, , IgA nephropathy (IgAN) in 1 case and focal segmental hyalinosis (FSH) in 2 cases. The aftermath of the RB were uneventful in all our patients. Medical termination of pregnancy was indicated in 3 cases of NL Class IV placed under corticosteroids + MMF in the first case and corticosteroids + cyclophosphamide in the second. The patient with EMG II was treated by corticosteroids + cyclosporine. Steroids should be prescribed in cases of glomerulonephritis MCD and FSH and EMG III. Therapeutic abstention with clinical and biological surveillance is indicated for patients with EMG I and IgAN.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.